Company / R&D Expense
Innoviva, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$30.6M
FY2025
5-year range
$576.0K / $33.9M
FY2021-FY2025
Trend
+124.1%
vs FY2024
Sector context
#192 of 210
Health Care
What the data says
Among 210 Health Care companies, Innoviva, Inc. is in the bottom 9% for r&d expense. R&D Expense has fluctuated over the past 10 years, ranging from $576,000 in FY2021 to $34M in FY2023.
Based on SEC 10-K filings.
$31M in FY2025 with a 5-year CAGR of +76.5%.
Declined from $34M to $31M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +157.7%
- 5-Year CAGR
- +76.5%
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 210This company $30.6M Sector average $644.0M
▼
-95.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +76.5%, indicating consistent growth.
- In FY2025, r&d expense increased 124.1% year-over-year.
- Ranks #192 out of 210 companies in the Health Care sector.
- Peak r&d expense was recorded in FY2023.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $30.6M | +124.1% |
| FY2024 | $13.7M | -59.7% |
| FY2023 | $33.9M | +1797.2% |
| FY2022 | $1.8M | +210.4% |
| FY2021 | $576.0K | -67.8% |
| FY2020 | $1.8M | +32.0% |
| FY2019 | $1.4M | -2.7% |
| FY2018 | $1.4M | +2.8% |
| FY2017 | $1.4M | -2.7% |
| FY2016 | $1.4M | -46.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026